| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| METIS TECHBIO Aktie jetzt für 0€ handeln | |||||
| Fr | METIS TECHBIO-P Plans On-mkt Share Buyback | 2 | AASTOCKS | ||
| Fr | METIS TECHBIO-P (07666): VOLUNTARY ANNOUNCEMENT ON-MARKET SHARE REPURCHASE UNDER GENERAL MANDATE | 1 | HKEx | ||
| Fr | Metis TechBio plans A-share listing | 1 | China Daily | ||
| Mi | METIS TECHBIO-P Proposes A-Share Listing Plan | 2 | AASTOCKS | ||
| Mi | METIS TECHBIO-P (07666): INSIDE INFORMATION PROPOSED A SHARE LISTING PLAN | 3 | HKEx | ||
| 19.10. | METIS TECHBIO-P (07666): VOLUNTARY ANNOUNCEMENT METIS TECHBIO ENTERED STRATEGIC COLLABORATION WITH LILLY TO ADVANCE NEXT-GENERATION TISSUE-SPECIFIC LNP ... | 2 | HKEx | ||
| 29.09. | METIS TECHBIO-P (07666): 2026 INTERIM REPORT | 4 | HKEx | ||
| 04.09. | METiS TechBio revenue surges on licensing deal | 2 | China Daily | ||
| 25.08. | METIS TECHBIO-P (07666): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | - | HKEx | ||
| 12.08. | METIS TECHBIO-P (07666): DATE OF BOARD MEETING | 1 | HKEx | ||
| 04.08. | METIS TECHBIO-P (07666): (1) APPOINTMENT OF JOINT COMPANY SECRETARY; AND (2) WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES | - | HKEx | ||
| 03.08. | METIS TECHBIO-P (07666): VOLUNTARY ANNOUNCEMENT METIS TECHBIO ANNOUNCES COLLABORATION WITH HENGRUI PHARMACEUTICALS ON THE AITEM ARTIFICIAL INTELLIGENCE ... | 2 | HKEx | ||
| 31.07. | METIS TECHBIO-P (07666): (1) RESIGNATION OF CHIEF FINANCIAL OFFICER, BOARD SECRETARY AND JOINT COMPANY SECRETARY AND CHANGE OF PROCESS AGENT; (2) CHANGE ... | 2 | HKEx | ||
| 30.06. | Deerfield's Boulevard Bio pens $1.6B deal for trispecific TCE from China's Metis TechBio | 2 | FierceBiotech | ||
| 30.06. | Metis TechBio seals $1.62b global licensing deal with Boulevard Bio | 1 | China Daily | ||
| 30.06. | METiS TechBio vergibt Lizenz für Wirkstoffkandidaten in 1,6-Milliarden-Dollar-Deal | - | Investing.com Deutsch | ||
| 30.06. | METiS TechBio licenses drug candidate to Boulevard Bio for $1.6B | 3 | Investing.com | ||
| 30.06. | METIS TECHBIO-P (07666): VOLUNTARY ANNOUNCEMENT METIS TECHBIO ANNOUNCES A PRECLINICAL TCE LICENSING COLLABORATION WITH DEERFIELD OF UP TO US$1.6 BILLION | 2 | HKEx | ||
| 22.06. | METIS TECHBIO-P (07666): NOTIFICATION LETTER TO NON-REGISTERED HOLDERS OF AND REQUEST FORM - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | - | HKEx | ||
| 22.06. | METIS TECHBIO-P (07666): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | 1 | HKEx |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 49,170 | -0,22 % | AstraZeneca Extends Tempus AI Partnership with $200 Million Commitment as Analyst Weighs Multiples | ||
| MANNKIND | 3,509 | 0,00 % | MannKind auf der Jefferies Global Healthcare Conference: Wachstumstreiber formieren sich - Profitabilität für Q4 2026 im Visier | ||
| NEOVACS | 0,043 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 22.10.2026 | Das Instrument 1DD FR001400H2X4 TONNER DRON. S.A.EO-,0001 EQUITY wird ex Kapitalmassnahme gehandelt am 22.10.2026 The instrument 1DD FR001400H2X4 TONNER DRON. S.A.EO-,0001 EQUITY is traded ex capital... ► Artikel lesen | |
| QIAGEN | 45,070 | -0,40 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| BEAM THERAPEUTICS | 20,900 | 0,00 % | Beam Therapeutics auf UBS-Konferenz: Forcierte Plattformstrategie und BLA-Antrag für Sichelzelltherapie in Sicht | ||
| PRAXIS PRECISION MEDICINES | 300,67 | +0,08 % | Praxis Precision Medicines: B.Riley initiiert Coverage mit "Buy" - Zulassungsentscheidungen rücken näher | ||
| DYNE THERAPEUTICS | 15,500 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ERASCA | 13,600 | -0,07 % | Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer | NEW YORK CITY (dpa-AFX) - Erasca, Inc. (ERAS) announced a clinical trial collaboration with Bristol Myers Squibb (BMY) to evaluate ERAS-0015, Erasca's investigational pan-RAS molecular glue... ► Artikel lesen | |
| CG ONCOLOGY | 79,58 | +0,14 % | Guggenheim raises CG Oncology stock price target on trial results | ||
| TARSUS PHARMACEUTICALS | 73,01 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care | Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved... ► Artikel lesen | |
| ABSCI | 7,510 | 0,00 % | Absci auf der Jefferies Global Healthcare Conference: Milliardenmarkt für neuartigen Haarausfall-Wirkstoff im Fokus | ||
| TREVI THERAPEUTICS | 13,350 | 0,00 % | Trevi Therapeutics: Wie ein Nischenmedikament zum strategischen Hebel für den Milliardenmarkt Reizhusten werden könnte | Trevi Therapeutics steht kurz davor, mit Haduvio ein erstes Nischenprodukt in den US-Markt zu bringen und damit einen "specialty beachhead" zu etablieren, der als Plattform für eine mögliche Expansion... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 9,970 | +0,20 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence | ||
| MBX BIOSCIENCES | 49,550 | 0,00 % | MBX Biosciences, Inc.: MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism | Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail results and durable one-year clinical benefit Global registrational trial to enroll approximately 160 adults with HP to support... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 46,490 | 0,00 % | Enliven Therapeutics auf der Jefferies-Konferenz: Fokus auf CML-Pivotalstudie und solide Liquidität |